度普利尤单抗治疗6个月至5岁重度特应性皮炎患儿
法国早期获取计划(EAP)纳入198例6个月至5岁重度特应性皮炎患儿,接受度普利尤单抗每4周皮下注射(按体重200或300 mg)。116例可评估患儿中,第6个月83.7%达到IGA 0/1,EASI 50/75/90分别为94.4%/75.0%/44.4%,67.6%瘙痒NRS改善≥4分,安全性与已知特征一致。
要点
- 6个月至5岁重度AD患儿中,度普利尤单抗第6个月83.7%达IGA 0/1。
- EASI 50/75/90应答率分别为94.4%/75.0%/44.4%,瘙痒NRS改善≥4分者67.6%。
- 安全性与度普利尤单抗已知安全性特征一致,未发现新信号。
核心结论
- 度普利尤单抗在6个月至5岁重度AD患儿中的有效性和安全性与临床研究中中重度AD患儿一致。
研究设计与样本
- 法国早期获取计划(EAP)的累积数据分析,共纳入198例6个月至5岁重度AD患儿(<2岁27例[13.6%],≥2岁171例[86.4%])。
- 患儿接受度普利尤单抗200 mg(≥5至<15 kg)或300 mg(≥15至<30 kg)每4周皮下注射,评估基线及随访第1、3、6个月。
主要发现
- 116例可评估患儿中,第6个月83.7%达到IGA 0/1,EASI 50/75/90分别为94.4%/75.0%/44.4%,67.6%达到P-NRS改善≥4分。
- 从治疗开始至第6个月,IGA、EASI和P-NRS评分平均±SD分别下降-2.1±1.2、-17.5±11.6和-4.4±2.8。
- IDQOL和CDLQI评分从治疗开始至第6个月分别平均±SD下降-6.9±6.6和-8.8±7.3。
- 安全性特征与度普利尤单抗已知安全性一致。
关键数值与推荐
- 重度AD患儿按体重给药:≥5至<15 kg用200 mg,≥15至<30 kg用300 mg,每4周一次。
- 疗效评估包括IGA、EASI 50/75/90、P-NRS、IDQOL(<4岁)和CDLQI(≥4岁)。
临床怎么用
- 对于6个月至5岁重度AD需系统治疗的患儿,度普利尤单抗每4周按体重给药可显著改善皮损、瘙痒和生活质量。
- 治疗6个月内应定期评估IGA、EASI、瘙痒NRS及生活质量,并监测安全性。
局限性
- 为早期获取计划的累积数据分析,可评估患儿116例,非对照研究设计。
- 随访时间为6个月,长期数据未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab, a human monoclonal anti-interleukin-4/13 antibody, is approved for treating severe atopic dermatitis (AD) in children aged 6 months-5 years. It received approval for an Early Access Program (EAP) for children by the French Health Authority in October 2022. OBJECTIVES: This EAP aims to evaluate the effectiveness and safety of dupilumab in children (aged 6 months-5 years) with severe AD requiring systemic treatment. METHODS: Cumulative data from the French EAP were analysed. Children with severe AD were administered dupilumab 200 and 300 mg (children ≥5 to <15 kg and ≥15 to <30 kg, respectively) every 4 weeks via a pre-filled syringe. The Investigator's Global Assessment (IGA), Eczema Area and Severity Index (EASI) 50/75/90, Pruritus-Numerical Rating Scale (P-NRS), Infants' Dermatitis Quality of Life Index (IDQOL; for children aged <4 years) and Children's Dermatology Life Quality Index (CDLQI; for children aged ≥4 years) scores were assessed at baseline and follow-up months (M) 1, 3 and 6. Safety was evaluated. RESULTS: A total of 198 children were enrolled (<2 years old: N = 27 [13.6%]; ≥2 years old: N = 171 [86.4%]). Of the 116 evaluated patients (exposed patients with at least ≥1 follow-up form), 83.7% achieved an IGA score of 0/1, 94.4%/75.0%/44.4% achieved an EASI 50/75/90, respectively, and 67.6% achieved a ≥4-point improvement in the P-NRS scores, at M6. The mean ± SD reduction from treatment initiation to M6 in the IGA, EASI and P-NRS scores was -2.1 ± 1.2, -17.5 ± 11.6 and -4.4 ± 2.8, respectively. The mean ± SD IDQOL and CDLQI scores reduced numerically from treatment initiation to M6 by -6.9 ± 6.6 and -8.8 ± 7.3, respectively. Safety was consistent with the established safety profile of dupilumab. CONCLUSIONS: The effectiveness and safety profile of dupilumab in children (aged 6 months-5 years) with severe AD were consistent with those reported in children with moderate-to-severe AD in clinical studies. Atopic dermatitis or eczema is a common skin disease that has a huge impact on the life of children and their family. Dupilumab has been proved to improve skin conditions of children in clinical trials. This EAP was conducted to provide the patients access to dupilumab, before its launch, and see how dupilumab treatment works in real life in children with eczema (especially infants under 2 years). Overall, 198 children with severe atopic dermatitis took part in this programme across 65 sites in France. They received dupilumab injections once every 4 weeks, and the dose of the drug was calculated based on their body weight. The healthcare professionals followed these children closely for any improvement in their eczema symptoms, quality of life and any side effects experienced by children, over 6 months while receiving dupilumab. Throughout this 6 months treatment period, the skin of ~84% of children became clear or almost clear, 75% of children saw the area affected by eczema reduce by at least three quarters, and ~68% of children felt less itchy. The quality of life of children also improved. While some children had minor side effects, these were not new and similar to what the healthcare professionals had seen in clinical trials of dupilumab. This EAP provides real‐world evidence that dupilumab treatment can help children as young as 6 months with severe atopic dermatitis, with results similar to those seen in clinical studies.
引用
- Lasek A, Bellon N, Mallet S, et al. Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2025. PMID: 41466122. doi:10.1111/jdv.70268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。